argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021

Rhea-AI Summary

On July 22, 2021, argenx (Euronext & Nasdaq: ARGX) announced a conference call scheduled for July 29, 2021, at 2:30 p.m. CET to discuss its half-year 2021 financial results and provide a business update for the second quarter. The live call will be accessible via the Investors section on the argenx website, with a replay available for a year. argenx focuses on innovative antibody-based therapies for severe autoimmune diseases and cancer, and is actively evaluating multiple candidates in serious indications.

Positive

• The upcoming conference call will provide insights into half-year financial performance.
• Discussions will cover updates on the company’s pipeline, including efgartigimod.

Negative

• None.

July 22, 2021

Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, July 29, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2021 financial results and provide a second quarter business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the call.

Dial-in numbers:
Please dial in 15 minutes prior to the live call.

Belgium                 0800 389 13
France                 0805 102 319
Netherlands                0800 949 4506
United Kingdom         0800 279 9489
United States 1 844 808 7140
International                    1 412 902 0128

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, Japan, and Switzerland. For more information, visit www.argenx.com and follow us on LinkedIn at https://www.linkedin.com/company/argenx/ and Twitter at https://twitter.com/argenxglobal.

For further information, please contact:

Media:
Kelsey Kirk
kkirk@argenx.com

Joke Comijn
jcomijn@argenx.com

Investors:

Beth DelGiacco
bdelgiacco@argenx.com

Michelle Greenblatt
mgreenblatt@argenx.com

FAQ

When will argenx announce its half-year 2021 financial results?

Argentx will announce its half-year 2021 financial results on July 29, 2021.

How can I access the argenx conference call?

The argenx conference call can be accessed via the Investors section of the argenx website.

What will be discussed during the argenx conference call?

The conference call will discuss the half-year financial results and provide a second quarter business update.

What is the focus of argenx in the biotech sector?

Argens focuses on developing antibody-based therapies for severe autoimmune diseases and cancer.